• Careers
  • Contact
Tavanta Tavanta
  • Company
    • About
    • Leadership
    • Partnering
    • Careers
    • Contact
  • Focus
    • Approach
    • Technology Platforms
    • Publications
  • Pipeline
    • Development Pipeline
    • TAVT-45
    • TAVT-119
    • Early Development Programs
  • Newsroom
    • Press Releases
Select Page
Tavanta
    • Company
      • About
      • Leadership
      • Partnering
      • Careers
      • Contact
    • Focus
      • Approach
      • Technology Platforms
      • Publications
    • Pipeline
      • Development Pipeline
      • TAVT-45
      • TAVT-119
      • Early Development Programs
    • Newsroom
      • Press Releases
    • Careers
    • Contact

Press Releases

Check out the latest news from Tavanta

September 18, 2019

DRGT Announces the U.S. FDA IND Application Approval and First Dosing of a Clinical Trial to Evaluate the Bioavailability and Food Effect of Immediate-Release Formulation of Tadalafil (DRGT-99)

July 15, 2019

DRGT Announces Hungarian Regulatory Authority Approval and Subsequent Initiation of a Phase 2 Trial of DRGT-119 in Patients With Chronic Anal Fissure

June 10, 2019

DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment Of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor

February 05, 2019

DRGT USA Announces Appointment of Dr. Elizabeth Manning Duus, as Executive Director of Clinical Development

December 06, 2018

Druggability Technologies USA Announces Appointment of John E. Friend II, M.D. as Chief Medical Officer

May 02, 2018

Best in Class Erectile Dysfunction Drug – DRGT announces dose escalation study results of its Super-Tadalafil DRGT-99

October 05, 2017

DRGT announces results of Phase I study expanding clinical utility of the drug Sirolimus utilizing the company’s novel Super-API technology platform

December 19, 2016

DRGT’s novel Celecoxib composition – opportunity for low dose, immediate onset of pain relief with the only NSAID COX-2 inhibitor on the market

<<123>>

Who We Are

LEARN ABOUT TAVANTA

COMPANY

  • About
  • Leadership
  • Partnering
  • Careers
  • Contact

FOCUS

  • Approach
  • Technology Platforms
  • Publications

PIPELINE

  • Development Pipeline
  • TAVT-45
  • TAVT-119
  • Early Development Programs

NEWSROOM

  • Press Releases
  • Privacy Policy
  • Terms of Use
Tavanta
©2020 Tavanta Therapeutics
  • Privacy Policy
  • Terms of Use

This site uses cookies to provide a better browsing experience. More information can be found on our Privacy Policy page.

ACCEPT